Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Bauer

Showing results (1-10 of 585) with videos related to

Pageof 59
Sort By:
Statistics in Medicine|December 6, 2016
Comments on 'Estimands in clinical trials - broadening the perspective'Peter Bauer
Biometrical Journal. Biometrische Zeitschrift|September 16, 2006
Methodological developments vs. regulatory requirementsPeter Bauer
Biometrical Journal. Biometrische Zeitschrift|April 22, 2017
Comment on 'A critical evaluation of the current "p-value controversy" 'Peter Bauer
Statistics in Medicine|October 16, 2007
Adaptive designs: looking for a needle in the haystack-a new challenge in medical researchPeter Bauer
Biometrical Journal. Biometrische Zeitschrift|September 16, 2006
Survival endpoints and adaptive designsPeter Bauer
Bioinformatics (Oxford, England)|April 28, 2007
Two-stage designs applying methods differing in costsAlexandra Goll, Peter Bauer
Nature Reviews. Drug Discovery|May 1, 2014
The risks of methodology aversion in drug regulationPeter Bauer, Franz König
JAMA Neurology|February 10, 2015
Autosomal recessive cerebellar ataxia 3 due to homozygote c.132dupA mutation within the ANO10 geneMartina Minnerop, Peter Bauer
Drug Discovery Today|April 15, 2004
The advantages and disadvantages of adaptive designs for clinical trialsPeter Bauer, Werner Brannath
Statistics in Biopharmaceutical Research|April 30, 2019
Adaptive Budgets in Clinical TrialsMartin Posch, Peter Bauer
Pageof 59

Showing results (1-10 of 585) with videos related to

Sort By:
Pageof 59
Statistics in Medicine|December 6, 2016
Comments on 'Estimands in clinical trials - broadening the perspective'Peter Bauer
Biometrical Journal. Biometrische Zeitschrift|September 16, 2006
Methodological developments vs. regulatory requirementsPeter Bauer
Biometrical Journal. Biometrische Zeitschrift|April 22, 2017
Comment on 'A critical evaluation of the current "p-value controversy" 'Peter Bauer
Statistics in Medicine|October 16, 2007
Adaptive designs: looking for a needle in the haystack-a new challenge in medical researchPeter Bauer
Biometrical Journal. Biometrische Zeitschrift|September 16, 2006
Survival endpoints and adaptive designsPeter Bauer
Bioinformatics (Oxford, England)|April 28, 2007
Two-stage designs applying methods differing in costsAlexandra Goll, Peter Bauer
Nature Reviews. Drug Discovery|May 1, 2014
The risks of methodology aversion in drug regulationPeter Bauer, Franz König
JAMA Neurology|February 10, 2015
Autosomal recessive cerebellar ataxia 3 due to homozygote c.132dupA mutation within the ANO10 geneMartina Minnerop, Peter Bauer
Drug Discovery Today|April 15, 2004
The advantages and disadvantages of adaptive designs for clinical trialsPeter Bauer, Werner Brannath
Statistics in Biopharmaceutical Research|April 30, 2019
Adaptive Budgets in Clinical TrialsMartin Posch, Peter Bauer
Pageof 59